With its dual-action on GLP-1 and GIP hormones, this once-weekly injection demonstrates a 20.9% weight loss during trials, making it appealing to those seeking enhanced effectiveness through a "semaglutide clinic near you." Foundayo (Orforglipron) For unparalleled dosing flexibility, Foundayo remains a prime choice
RESEARCH HIGHLIGHT Pairing up with GLP-1 to combat obesity Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Nature Reviews Drug Discovery 24 , 89 (2025) doi: References Polex-Wolf, J
Safety Profile: Common Side Effects : Nausea, vomiting, and diarrhea are the most commonly reported side effects
Evidence-based medicine requires robust research demonstrating both efficacy and safety before treatments can be recommended
If significant deficiency is confirmed via blood test, a loading dose protocol may be recommended in line with NICE guidance typically more frequent injections over the initial weeks to rapidly restore levels